SUCRAID Drug Profile

Summary for Tradename: SUCRAID

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for SUCRAID
Recent Clinical Trials:	See clinical trials for SUCRAID

See drug prices for SUCRAID

Recent Clinical Trials for SUCRAID

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
QOL Medical, LLC	Phase 4

See all SUCRAID clinical trials

Pharmacology for SUCRAID

Established Pharmacologic Class

Sucrose-specific Enzyme

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SUCRAID Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SUCRAID Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SUCRAID Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772		2033-03-11	Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772		2029-05-13	Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772		2034-02-07	Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772		2038-07-09	Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772			Patent claims search
Qol Medical, Llc	SUCRAID	sacrosidase	Solution For Oral	020772		2040-03-31	Patent claims search

SUCRAID Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for the Biologic Drug: Sucraid

Introduction

Sucraid, also known as sacrosidase, is a biologic drug used for the treatment of symptoms associated with sucrose ingestion in patients with a rare gastrointestinal genetic disorder called Congenital Sucrase-Isomaltase Deficiency (CSID). Here, we will delve into the market dynamics and financial trajectory of Sucraid, highlighting key factors influencing its market presence.

Market Overview

Sucraid is a specialized enzyme replacement therapy, and its market is niche due to the rarity of the condition it treats. Here are some key points about the market:

Rare Disease Market

Sucraid operates within the rare disease market, which is characterized by a small patient population but often high treatment costs. This segment is growing due to advancements in biotechnology and increased awareness of rare diseases[3].

Competition

The biologic drug market, particularly for rare diseases, is not highly competitive in terms of direct substitutes. However, the presence of dietary management options and other supportive treatments can influence the demand for Sucraid.

Demand and Patient Base

Patient Population

The demand for Sucraid is driven by the need to manage CSID, a condition that affects a small but significant number of patients. The rarity of the disease means that the patient base is limited, but the necessity of the treatment ensures a consistent demand.

Geographic Distribution

The demand for Sucraid is global, but it is more pronounced in regions with better healthcare infrastructure and higher awareness of rare diseases. In the United States, for example, there are specific programs to support patients with CSID[5].

Financial Assistance Programs

Given the high cost of biologic treatments, financial assistance programs play a crucial role in making Sucraid accessible to patients.

SucraidASSIST™

The SucraidASSIST™ program offers financial support to eligible patients, including those who are uninsured or underinsured. This program helps in connecting patients with available financial assistance, such as copay and deductible savings, and ensures that the treatment remains affordable for those who need it[5].

Market Challenges

Supply Chain Issues

Sucraid has faced supply chain issues in the past, leading to limited availability. The FDA has had to intervene to manage the distribution and ensure that patients with severe CSID have access to the medication[4].

Regulatory Environment

The regulatory environment for biologic drugs is stringent, and any changes in regulations can impact the market dynamics. For Sucraid, maintaining FDA approval and compliance is crucial for its continued availability.

Financial Trajectory

Revenue and Sales

While specific revenue figures for Sucraid are not publicly available, the overall biologic drug market is growing. Biologics now represent 42% of the total medicines market, up from 30% in 2014, indicating a strong financial trajectory for biologic treatments in general[3].

Cost and Pricing

The cost of Sucraid is significant, reflecting the high development and production costs associated with biologic drugs. Financial assistance programs help mitigate these costs for patients, but the overall expense remains a challenge.

Key Players and Market Share

Sucraid is manufactured by QOL Medical, LLC, which plays a critical role in the supply and distribution of the drug. The company's efforts in managing supply chain issues and providing financial assistance are key to maintaining market share.

Future Outlook

Growing Awareness

Increasing awareness of rare diseases and advancements in biotechnology are expected to drive the demand for specialized treatments like Sucraid.

Regulatory Changes

Changes in regulatory policies, especially those related to biosimilars, could impact the market dynamics for biologic drugs. However, since Sucraid is a unique enzyme replacement therapy, it is less likely to face immediate competition from biosimilars[3].

Key Takeaways

• Niche Market: Sucraid operates in a niche market due to the rarity of CSID.
• Financial Assistance: Programs like SucraidASSIST™ are crucial for making the treatment affordable.
• Supply Chain: Managing supply chain issues is essential to ensure consistent availability.
• Regulatory Environment: Compliance with FDA regulations is vital for the drug’s continued market presence.
• Growing Demand: Increasing awareness and advancements in biotechnology are expected to drive demand.

FAQs

What is Sucraid used for?

Sucraid, or sacrosidase, is used for the treatment of symptoms associated with sucrose ingestion in patients with Congenital Sucrase-Isomaltase Deficiency (CSID).

Why is Sucraid often in short supply?

Sucraid has faced supply chain issues, leading to limited availability. The FDA works closely with the manufacturer to manage the distribution and ensure access for patients with severe CSID[4].

How can patients afford Sucraid?

Patients can benefit from financial assistance programs like SucraidASSIST™, which offers copay and deductible savings and other forms of financial support[5].

Is Sucraid a biologic drug?

Yes, Sucraid is a biologic drug, specifically an enzyme replacement therapy.

What are the key challenges for Sucraid in the market?

Key challenges include supply chain issues, high costs, and the need for stringent regulatory compliance.

Sources

1. FDA: Related Information for Sacrosidase Oral Solution - FDA[4]
2. SucraidASSIST™: Financial Support Services for Patients[5]
3. IQVIA: Biologics Market Dynamics: Setting the Stage for Biosimilars[3]